The tumor microenvironment in hepatocarcinoma: dissecting the functions of cancer-associated fibroblasts

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, deriving from the neoplastic transformation of hepatocytes, most often forced to long-lasting regeneration by the cirrhotic background. HCC is an extremely aggressive tumor with still limited effective treatments, and is characterized by the presence of a very complex and multifaceted tumor microenvironment (TME). Among the variety of cell types populating the TME of HCC, cancer-associated fibroblasts (CAFs) are the most prevalent. CAFs are a specific population of fibroblasts in a persistent state of activation, with a high level of heterogeneity, partly dependent on a wide range of cell origin, which are endowed with a repertoire of functions, profoundly modulating the biology of the tumor. Given the close relationship of HCC with cirrhosis, CAFs are paradigmatic of the role played by activated fibroblasts in promoting the evolution of a chronic, non-resolving, fibro-inflammatory condition towards a neoplastic disease and its aggressive phenotype. In this review, we will discuss the most recent findings regarding the interplay of CAFs with the tumoral epithelial compartment, with the multiple cell elements of the TME (macrophages, neutrophils, myeloid-derived suppressor cells, vascular cells), and with the extracellular matrix. Finally, we will address the translational value of CAF manipulation in HCC to unveil possible ameliorations for the treatment of a still worrisome disease.

Keywords

Cancer-associated fibroblasts / tumor immune microenvironment / CAF heterogeneity / extracellular matrix remodeling / tumor-associated macrophages

References

[1] Llovet JM,Villanueva A.Hepatocellular carcinoma.Nat Rev Dis Primers2021;7:6

[2] Myers S,Spahr L.NAFLD and MAFLD as emerging causes of HCC: a populational study.JHEP Rep2021;3:100231 PMCID:PMC7957147

[3] Vitale A,Ortolani A.Italian Liver Cancer (ITALI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.Gut2023;72:141-52

[4] Ping Q,Cheng X.Cancer-associated fibroblasts: overview, progress, challenges, and directions.Cancer Gene Ther2021;28:984-99

[5] Kubo N,Kuwano H.Cancer-associated fibroblasts in hepatocellular carcinoma.World J Gastroenterol2016;22:6841-50 PMCID:PMC4974583

[6] Baglieri J,Kisseleva T.The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma.Int J Mol Sci2019;20:1723 PMCID:PMC6479943

[7] Wright K,Kriet M,Thomas SM.Cancer-associated fibroblasts: master tumor microenvironment modifiers.Cancers2023;15:1899 PMCID:PMC10047485

[8] Minini M.Cancer-associated fibroblasts and extracellular matrix: therapeutical strategies for modulating the cholangiocarcinoma microenvironment.Curr Oncol2023;30:4185-96 PMCID:PMC10137461

[9] Donne R.The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma.Hepatology2023;77:1773-96 PMCID:PMC9941399

[10] Feng H,Zhang X.Tumor microenvironment in hepatocellular carcinoma: key players for immunotherapy.J Hepatocell Carcinoma2022;9:1109-25 PMCID:PMC9618253

[11] Liu Y,Ma K.Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.J Hepatol2023;78:770-82

[12] Tao ZW,Zhou T.Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review.Hepatobiliary Pancreat Dis Int2022;21:134-44

[13] Malehmir M,Gallage S.Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.Nat Med2019;25:641-55

[14] Zhu AX,Sahani DV.HCC and angiogenesis: possible targets and future directions.Nat Rev Clin Oncol2011;8:292-301 PMCID:PMC3266719

[15] Llovet JM,Heikenwalder M.Immunotherapies for hepatocellular carcinoma.Nat Rev Clin Oncol2022;19:151-72

[16] Ying F,Lee TKW.Cancer-associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma.Cell Mol Gastroenterol Hepatol2023;15:985-99 PMCID:PMC10040968

[17] Yu L,Shi Y.Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.Front Immunol2022;13:1009789 PMCID:PMC9537943

[18] Chiavarina B,Otaka Y.Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma.Oncogene2022;41:1410-20

[19] Han C,Yin R.Biomarkers for cancer-associated fibroblasts.Biomark Res2020;8:64 PMCID:PMC7661188

[20] Wu F,Liu J.Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.Signal Transduct Target Ther2021;6:218 PMCID:PMC8190181

[21] Zhou Y,Dai B.Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts.J Exp Clin Cancer Res2018;37:324 PMCID:PMC6307162

[22] Mederacke I,Troeger JS.Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.Nat Commun2013;4:2823 PMCID:PMC4059406

[23] Wang SS,Lin M.Perivenous stellate cells are the main source of myofibroblasts and cancer-associated fibroblasts formed after chronic liver injuries.Hepatology2021;74:1578-94

[24] Filliol A,Nair A.Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis.Nature2022;610:356-65 PMCID:PMC9949942

[25] Zhang J,Song Q.Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma.Cell Biosci2020;10:127 PMCID:PMC7603733

[26] Dranoff JA.Portal fibroblasts: underappreciated mediators of biliary fibrosis.Hepatology2010;51:1438-44 PMCID:PMC2850946

[27] Iwaisako K,Zhang M.Origin of myofibroblasts in the fibrotic liver in mice.Proc Natl Acad Sci U S A2014;111:E3297-305 PMCID:PMC4136601

[28] Nishio T,Koyama Y.Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.J Hepatol2019;71:573-85

[29] Yang W,Wang T.Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice.Hepatology2021;74:2774-90 PMCID:PMC859710

[30] Quan TE.Culture and analysis of circulating fibrocytes.Methods Mol Med2007;135:423-34

[31] Kisseleva T,Feirt N.Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis.J Hepatol2006;45:429-38

[32] Yin Z,Li R,Wang L.Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy.Mol Cancer2018;17:178 PMCID:PMC6309092

[33] Salah RA,El-Derby AM.Hepatocellular carcinoma cell line-microenvironment induced cancer-associated phenotype, genotype and functionality in mesenchymal stem cells.Life Sci2022;288:120168

[34] Zeisberg M.Biomarkers for epithelial-mesenchymal transitions.J Clin Invest2009;119:1429-37 PMCID:PMC2689132

[35] Kalluri R.The basics of epithelial-mesenchymal transition.J Clin Invest2009;119:1420-8 PMCID:PMC2689101

[36] Acloque H,Fishwick K,Nieto MA.Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease.J Clin Invest2009;119:1438-49 PMCID:PMC2689100

[37] Strutz F,Ziyadeh FN.Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation.Kidney Int2002;61:1714-28

[38] Ye X.Epithelial-mesenchymal plasticity: a central regulator of cancer progression.Trends Cell Biol2015;25:675-86 PMCID:PMC4628843

[39] Zhu G,Tang Q.An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients.Cancer Cell Int2021;21:166 PMCID:PMC7953549

[40] Kong W,Han C.A novel epithelial-mesenchymal transition gene signature correlated with prognosis, and immune infiltration in hepatocellular carcinoma.Front Pharmacol2022;13:863750 PMCID:PMC9065556

[41] Zeisberg M,Martino M.Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition.J Biol Chem2007;282:23337-47

[42] Taura K,Iwaisako K.Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice.Hepatology2010;51:1027-36 PMCID:PMC2906231

[43] Chu AS,Hui JJ.Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis.Hepatology2011;53:1685-95 PMCID:PMC3082729

[44] Huang H,Zhang Y.Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer.Cancer Cell2022;40:656-73.e7 PMCID:PMC9197998

[45] Elyada E,Laise P.Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts.Cancer Discov2019;9:1102-23 PMCID:PMC6727976

[46] Kerdidani D,Verrou KM.Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts.J Exp Med2022;219:e20210815 PMCID:PMC8764966

[47] Lau EYT,Cheng BYL.Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through C-Met/FRA1/HEY1 signaling.Cell Rep2016;15:1175-89

[48] Xiong S,Chen Q.Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling.Am J Cancer Res2018;8:302-16 PMCID:PMC5835697

[49] Liu C,Chen X.LSD1 stimulates cancer-associated fibroblasts to drive notch3-dependent self-renewal of liver cancer stem-like cells.Cancer Res2018;78:938-49

[50] Song M,Pan QZ.Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression.Hepatology2021;73:1717-35

[51] Bai S,Chen W.The stromal-tumor amplifying STC1-Notch1 feedforward signal promotes the stemness of hepatocellular carcinoma.J Transl Med2023;21:236 PMCID:PMC10067215

[52] Li Q,Wang Y.HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.J Exp Clin Cancer Res2018;37:231 PMCID:PMC6146743

[53] Xu H,Li J.Cancer associated fibroblast-derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1α/ZEB1 axis.Cell Death Dis2022;13:478 PMCID:PMC9119971

[54] Liu J,Wang W.Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways.Cancer Lett2016;379:49-59

[55] Liu G,Yang ZF.Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis.Cell Death Dis2021;12:260 PMCID:PMC7952559

[56] Mazzocca A,Dituri F,Antonaci S.Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.Hepatology2010;51:523-34

[57] Kitisin K,Johnson LB.Liver stem cells and molecular signaling pathways in hepatocellular carcinoma.Gastrointest Cancer Res2007;1:S13-21 PMCID:PMC2666844

[58] Yoshida GJ.Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways.J Exp Clin Cancer Res2020;39:112 PMCID:PMC7296768

[59] Collier JD,Gullick WJ,Burt AD.Expression of transforming growth factor alpha in human hepatocellular carcinoma.Liver1993;13:151-5

[60] Capece D,Verzella D.The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages.Biomed Res Int2013;2013:187204 PMCID:PMC3591180

[61] Baek JY,Campbell J,Yeh MM.TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer.Int J Cancer2010;127:1060-71 PMCID:PMC2897914

[62] Thoresen GH,Sandnes D,Agius L.Response to transforming growth factor α (TGFα) and epidermal growth factor (EGF) in hepatocytes: Lower EGF receptor affinity of TGFα is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis.J Cell Physiol1998;175:10-8

[63] Schiffer E,Cacheux W.Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.Hepatology2005;41:307-14

[64] Sun L,Wang L.Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP.J Exp Clin Cancer Res2019;38:170 PMCID:PMC6472102

[65] Fiaschi T,Giannoni E.Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay.Cancer Res2012;72:5130-40

[66] Martinez-Outschoorn UE,Lisanti MP.Metabolic asymmetry in cancer: a "balancing act" that promotes tumor growth.Cancer Cell2014;26:5-7

[67] Martinez-Outschoorn UE,Sotgia F.Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth.Semin Cancer Biol2014;25:47-60

[68] Yuan Q,Liu Y.MyD88 in myofibroblasts regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation.J Pathol2022;256:414-26

[69] De Matteis S,Marisi G.Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities.Oxid Med Cell Longev2018;2018:7512159 PMCID:PMC6247426

[70] Oura K,Tani J.Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review.Int J Mol Sci2021;22:5801 PMCID:PMC8198390

[71] Noy R.Tumor-associated macrophages: from mechanisms to therapy.Immunity2014;41:49-61 PMCID:PMC4137410

[72] Arvanitakis K,Mitroulis I.Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy.Cancers2022;14:226 PMCID:PMC8749970

[73] Feig C,Kraman M.Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.Proc Natl Acad Sci U S A2013;110:20212-7 PMCID:PMC3864274

[74] Yang F,Han D.Interaction with CD68 and regulation of GAS6 expression by endosialin in fibroblasts drives recruitment and polarization of macrophages in hepatocellular carcinoma.Cancer Res2020;80:3892-905

[75] Chen S,Tokuda K.Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway.Int J Oncol2021;59:59 PMCID:PMC8253588

[76] Fabregat I.Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis.Front Oncol2018;8:357 PMCID:PMC6139328

[77] Zulaziz N,Lim KP.The origins, roles and therapies of cancer associated fibroblast in liver cancer.Front Oncol2023;13:1151373 PMCID:PMC10076538

[78] Higashino N,Hosono M.Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.Lab Invest2019;99:777-92

[79] Zheng T,Tang M,Xu R.IL-8 secreted from M2 macrophages promoted prostate tumorigenesis via STAT3/MALAT1 pathway.Int J Mol Sci2018;20:98 PMCID:PMC6337597

[80] Hosono M,Takase N.CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells.Oncotarget2017;8:106071-88 PMCID:PMC5739702

[81] Li J,Chen L.Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression.PLoS One2012;7:e46264 PMCID:PMC3457978

[82] Cao L,Jing W.Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.Oncotarget2015;6:6627-40 PMCID:PMC4466639

[83] Zhou SL,Hu ZQ.Tumor-associated neutrophils recruit macrophages and t-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib.Gastroenterology2016;150:1646-58.e17

[84] Zhou SL,Hu ZQ.A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression.Hepatology2019;70:1214-30

[85] Xu M,Song J.Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.Exp Cell Res2017;351:142-9

[86] Wang W,Ji M.Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment.J Transl Med2020;18:477 PMCID:PMC7733302

[87] Huang B,Zhao J.CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.Cancer Lett2007;252:86-92

[88] Hoechst B,Ormandy L.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.Hepatology2009;50:799-807 PMCID:PMC6357774

[89] Yang X,Shi Y.FAP Promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling.Cancer Res2016;76:4124-35

[90] Cadamuro M,Guido M.Translational value of tumor-associated lymphangiogenesis in cholangiocarcinoma.J Pers Med2022;12:1086 PMCID:PMC9324584

[91] Cadamuro M,Mertens J.Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.J Hepatol2019;70:700-9

[92] Huynh PT,Coronado YA.CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer.Int J Cancer2016;138:1971-81 PMCID:PMC4865268

[93] Liu Z,Zhao R.CAF-induced placental growth factor facilitates neoangiogenesis in hepatocellular carcinoma.Acta Biochim Biophys Sin2020;52:18-25

[94] Sukowati CHC,Crocé LS.The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis.BMC Cancer2015;15:188 PMCID:PMC4389787

[95] Lin N,Lin J.Activated hepatic stellate cells promote angiogenesis in hepatocellular carcinoma by secreting angiopoietin-1.J Cell Biochem2020;121:1441-51

[96] Huang B,Li Q.Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by VEGF-mediated EZH2/VASH1 pathway.Technol Cancer Res Treat2019;18:1533033819879905 PMCID:PMC6876164

[97] Shirai T,Sasaki T.Cancer-associated fibroblasts promote venous thrombosis through podoplanin/CLEC-2 interaction in podoplanin-negative lung cancer mouse model.J Thromb Haemost2023;21:3153-65

[98] Krishnan H,Miyashita T.Podoplanin: an emerging cancer biomarker and therapeutic target.Cancer Sci2018;109:1292-9 PMCID:PMC5980289

[99] Sasano T,Muñoz NM.Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer.J Thromb Haemost2022;20:104-14 PMCID:PMC8712373

[100] Fabris L,Cagnin S,Gores GJ.Liver matrix in benign and malignant biliary tract disease.Semin Liver Dis2020;40:282-97

[101] Cadamuro M,Brivio S.The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.Biochim Biophys Acta Mol Basis Dis2018;1864:1435-43 PMCID:PMC6386155

[102] Filliol A.Contributions of fibroblasts, extracellular matrix, stiffness, and mechanosensing to hepatocarcinogenesis.Semin Liver Dis2019;39:315-33

[103] Affo S,Schwabe RF.The role of cancer-associated fibroblasts and fibrosis in liver cancer.Annu Rev Pathol2017;12:153-86 PMCID:PMC5720358

[104] Lai KK,Lohia N.Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models.PLoS Genet2011;7:e1002147 PMCID:PMC3121762

[105] Liu XY,Hou F.Fibronectin expression is critical for liver fibrogenesis in vivo and in vitro.Mol Med Rep2016;14:3669-75 PMCID:PMC5042748

[106] Matsuo M,Ueno Y,Saiki I.Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.Cancer Sci2006;97:155-62

[107] Fransvea E,Antonaci S.Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.Hepatology2009;49:839-50

[108] Zheng X,Li L.Cancer-associated fibroblasts promote vascular invasion of hepatocellular carcinoma via downregulating decorin-integrin β1 signaling.Front Cell Dev Biol2021;9:678670 PMCID:PMC8421641

[109] Giannelli G,Bergamini C,Antonaci S.Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma.Clin Cancer Res2003;9:3684-91

[110] Bergamini C,Trerotoli P.Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins.Hepatology2007;46:1801-9

[111] Ke AW,Zhou J.CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells.Gastroenterology2011;140:1629-41.e15

[112] Zhang R,Li JH.Activated hepatic stellate cells secrete periostin to induce stem cell-like phenotype of residual hepatocellular carcinoma cells after heat treatment.Sci Rep2017;7:2164 PMCID:PMC5438402

[113] Zhao M,Zimmermann A.Tenascin and type IV collagen expression in liver cell dysplasia and in hepatocellular carcinoma.Histol Histopathol1996;11:323-33

[114] Nong Y,Lin Y,Bai L.Tenascin-C expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients and the inflammatory cytokine TNF-α-induced TNC expression promotes migration in HCC cells.Am J Cancer Res2015;5:782-91 PMCID:PMC4396033

[115] Passi M.Mechano-signaling aspects of hepatocellular carcinoma.J Cancer2021;12:6411-21 PMCID:PMC8489129

[116] Wei J,Yang C.Heterogeneous matrix stiffness regulates the cancer stem-like cell phenotype in hepatocellular carcinoma.J Transl Med2022;20:555 PMCID:PMC9719217

[117] Kaps L.Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers.Cells2020;9:2027 PMCID:PMC7563527

[118] Mertens JC,Christensen JD.Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.Cancer Res2013;73:897-907 PMCID:PMC3549008

[119] Morén A,Tsubakihara Y.LXRα limits TGFβ-dependent hepatocellular carcinoma associated fibroblast differentiation.Oncogenesis2019;8:36 PMCID:PMC6522550

[120] Shankaraiah RC,Guerriero P.Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.Oncogene2019;38:7035-45

[121] Mano Y,Shoji H.Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.J Gastroenterol2019;54:1007-18

[122] Kelly T.Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy.Drug Resist Updat2005;8:51-8

[123] Chen A,Luo Y.Disruption of crosstalk between LX-2 and liver cancer stem-like cells from MHCC97H cells by DFOG via inhibiting FOXM1.Acta Biochim Biophys Sin2019;51:1267-75